Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics

Journal of Hepatology

Volumn 39, Issue SUPPL. 1, 2003, Pages

  Pawlotsky, Jean Mihael ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ALPHA2B INTERFERON; ENTECAVIR; LAMIVUDINE; VIRUS DNA;

ACUTE HEPATITIS; CHRONIC HEPATITIS; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DNA DETERMINATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MEDICAL DECISION MAKING; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; VIRUS REPLICATION;

EID: 0141526168     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(03)00136-3     Document Type: Conference Paper

References (47)

1. Whalley SA, Murray JM, Brown D, Webster GJM, Emery VC, Dusheiko GM, et al. Kinetics of acute hepatitis B virus infection in humans. J Exp Med 2001;193:847-53.
2. Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology 2002;122:1554-68.
3. Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 2001;80:63-71.
4. Aspinall S, Steele AD, Peenze I, Mphahlele MJ. Detection and quantitation of hepatitis B virus DNA: comparison of two commercial hybridization assays with polymerase chain reaction. J Viral Hepat 1995;2:107-11.
5. Barlet V, Cohard M, Thelu MA, Chaix MJ, Baccard C, Zarski JP, et al. Quantitative detection of hepatitis B virus DNA in serum using chemiluminescence: comparison with radioactive solution hybridization assay. J Virol Methods 1994;49:141-51.
6. Krajden M, Minor J, Cork L, Comanor L. Multi-measurement method comparison of three commercial hepatitis B virus DNA quantification assays. J Viral Hepat 1998:5:415-22.
7. Chan HL, Leung NW, Lau TC, Wong ML, Sung JJ. Comparison of three different sensitive assays for hepatitis B virus DNA in monitoring of responses to antiviral therapy. J Clin Microbiol 2000;38:3205-8.
8. Hendricks DA, Stowe BJ, Hoo BS, Kolberg J, Irvine BD, Neuwald PD, et al. Quantitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay. Am J Clin Pathol 1995;104:537-46.
9. Ho SK, Chan TM, Cheng IK, Lai KN. Comparison of the second-generation Digene hybrid capture assay with the branched-DNA assay for measurement of hepatitis B virus DNA in serum. J Clin Microblol 1999;37:2461-5.
10. Niesters HG, Krajden M, Cork L, de Medina M, Hill M, Fries E, et al. A multicenter study evaluation of the Digene hybrid capture II signal amplification technique for detection of hepatitis B virus DNA in serum samples and testing of EUROHEP standards. J Clin Microbiol 2000;38:2150-5.
11. Pawlotsky JM, Bastie A, Lonjon I, Remire J, Darthuy F, Soussy CJ, et al. What technique should be used for routine detection and quantification of HBV DNA in clinical samples? J Virol Methods 1997;65:245-53.
12. Pawlotsky JM, Bastie A, Hezode C, Lonjon I, Darthuy F, Remire J, et al. Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays. J Virol Methods 2000;85:11-21.
13. Poljak M, Matin IJ, Seme K, Brinovec V, Maticic M, Meglic-Volkar J, et al. Second-generation Hybrid capture test and Amplicor Monitor test generate highly correlated hepatitis B virus DNA levels. J Virol Methods 2001;97:165-9.
14. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B 2000: summary of a workshop. Gastroenterology 2001;120:1828-53.
15. Martinot-Peignoux M, Boyer N, Colombat M, Akremi R, Pham BN, Ollivier S, et al. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 2002;36:543-6.
16. Manesis EK, Papatheodoridis GV, Hadziyannis SJ. Serum HBV-DNA levels in inactive hepatitis B virus carriers. Gastroenterology 2002;122:2092-3.
17. Chu CJ, Lok ASF. Clinical utility in quantifying serum HBV DNA levels using PCR assays. J Hepatol 2002;36:549-51.
18. Perrillo RP, Schiff ER, Davis GL, Bodenheimer Jr HC, Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301.
19. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
20. Lok AS, Lai CL, Wu PC, Leung EK. Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988;2:298-302.
21. Lai CL, Lok AS, Lin HJ, Wu PC, Yeoh EK, Yeung CY. Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children. Lancet 1987;2:877-80.
22. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
23. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A 1-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-8.
24. Cooksley WGE, Piratvisuth T, Wang YJ, Mahachai V, Chao YC, Tanwandee T, et al. Evidence for the efficacy of peginterferon alfa-2a (40 kD) (Pegasys) in the treatment of HBeAg-positive chronic hepatitis B and impact of baseline factors. J Hepatol 2002;36:8.
25. Sypsa V, Tassopoulos NC, Chrysagis D, Mimidis K, Vassiliadis T, Raptopoulou M, et al. A viral kinetic study using pegylated interferon alpha-2b and lamivudine in naive patients with HBeAg(-)/HBV DNA(+) chronic hepatitis B: preliminary results. J Hepatol 2002;36:94.
26. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001;358:718-23.
27. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-34.
28. Xiong X, Flores C, Yang H? Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998;28:1669-73.
29. Zollner B, Petersen J, Schroter M, Laufs R, Schoder V, Feucht HH. Twenty-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 2001;357:934-5.
30. Schalm SW. Clinical implications of lamivudine resistance by HBV. Lancet 1997;349:3-4.
31. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001;34:411-6.
32. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y. et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32:828-34.
33. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-10.
34. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30:1302-6.
35. Dienstag JL, Schiff ER, Mitchell M, Casey Jr DE, Gitlin N, Lissoos T, et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999;30:1082-7.
36. Tillmann HL, Trautwein C, Bock T, Boker KH, Jackel E, Glowienka M, et al. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology 1999;30:244-56.
37. Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999;29:1581-6.
38. Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ, et al. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 1999;29:939-45.
39. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714-7.
40. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996;93.
41. Zeuzem S, De Man RA, Honkoop P, Roth WK, Schalm SW, Schmidt JM. Dynamics of hepatitis B virus infection in vivo. J Hepatol 1997;27:431-6.
42. Wolters LLM, Hansen BE, Niesters HGM, Levi-Drummer RS, Neumann AU, Schalm SW, et al. The influence of baseline characteristics on viral dynamics parameters in chronic hepatitis B patients treated with lamivudine. J Hepatol 2002;37:253-8.
43. Lau GKK, Tsiang M, Hou J, Yuen ST, Carman WF, Zhang L, et al. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. Hepatology 2000;32:394-9.
44. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999;29:1863-9.
45. Wolters LLM, Hansen BE, Niesters HG, De Hertogh D, De Man RA. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol 2002;37:137-44.
46. Neumann AU, Havlin Y, Tal R, Tsiang M, Wulfsohn M, Brosgart C. Long-term HBV, et al. kinetics classification during treatment with adefovir dipivoxil. J Hepatol 2002;36:121.
47. Werle B, Wursthorn K, Petersen J, Bowden S, Locamini S, James C, et al. Development of a quantitative assay for hepatic HBV cccDNA levels in patients with chronic hepatitis B. J Hepatol 2002;36:4.